• Adenovirus Service • AAV Service • Lentivirus Service • Retrovirus Service
The 2019 novel coronavirus (2019-nCoV) has spread rapidly since its identification in patients with severe pneumonia in Wuhan, China. As of 14 February 2020, 2019-nCoV has been reported in 25 countries across 4 continents and >60,000 cases have been confirmed, with an estimated mortality risk of ~2%.
The existence of coronavirus has long been known. As a virus that can infect the respiratory and digestive tracts of animals and humans, it has not received enough attention from humans for a long time. This arrogance is also excusable - in healthy people with normal immunity, coronaviruses cause only very mild symptoms. However, during the first decade of the 21st century, SARS broke out. In July 2003, data showed that the SARS virus caused 8096 cases of infection and 774 people death in 27 countries. 10 years later, the Middle East Respiratory Syndrome caused by the MERS virus brought 1,728 confirmed cases in 27 countries and claimed 624 lives.
In the wave of gene therapy recently being developed by academic research laboratories and biotechnology laboratories, adeno-associated virus (AAV) has become the carrier of choice for delivering therapeutic genes to target tissues.
Recently, a research report published in the international magazine PNAS, scientists from the Duke University Medical Center found that a particular genetic predisposition may increase the risk of an individual successfully resisting drug-resistant staphylococcus aureus infection. The findings help researchers understand the specific genetic factors that make certain people susceptible to MRSA (methicillin-resistant staphylococcus aureus) infection and help researchers find new therapy to defense against MRSA infection.
Cancer is a chronic disease in which leads millions of people to die every year from worldwide. According to the World Health Organization (WHO), there are about 18 million people diagnosed with cancer worldwide in 2018, and more than 9 million people will die of cancer. By 2030, the number of newly confirmed cases will exceed 23 million each year. The most common types of cancer include lung cancer, breast cancer and colorectal cancer.
Lentivirus (Lentivirus) vector is gene therapy vectors, which is based on HIV-1 (human immunodeficiency virus type I). Compared to those general retroviral vectors, it has the ability to infect dividing cells and non-dividing cells. Lentiviral can produce the high-titer lentiviral, which can be used in shRNA expression.
This blog article is to discuss classification of cell transfection technology, as well as introducing the principles, applications and characteristics of different methods, and to compare various of transfection methods.
Lentivirus is classified as retroviridae. The pre-integration complex of the lentivirus nuclear protein has the characteristics of phagocytosis, and the viral genome translocates to the nucleus, so that it can infect and replicate in the non-mitotic cells. This feature makes it an ideal transfer vector for gene therapy.
